JD Health Schedules 29 June 2026 AGM; Seeks Renewal of 20% Issue Mandate, 10% Buy-back Authority and Board Re-elections

Bulletin Express
06/05

JD Health International Inc. will hold its Annual General Meeting on 29 June 2026 at 10:00 a.m. at its Yizhuang headquarters in Beijing. Key resolutions include:

1. Capital Mandates • A new general mandate authorising directors to allot and issue up to 20% of the issued share capital, equivalent to 639.83 million shares based on the 3.20 billion shares outstanding (excluding treasury and pending-cancellation shares) as at 26 May 2026. • A repurchase mandate permitting buy-backs of up to 10% of shares in issue, or 319.92 million shares. • An extension mandate allowing the issue limit to be increased by any shares repurchased under the buy-back authority. If approved, the mandates will remain effective until the next AGM or earlier revocation.

2. Board Composition Shareholders will vote on the re-election of: • Dong Cao, Chief Executive Officer (executive director). • Richard Qiangdong Liu, Chairman (non-executive director). • Ling Li, Chair of the Remuneration Committee (independent non-executive director).

3. Auditor Deloitte Touche Tohmatsu is nominated for re-appointment as external auditor for 2026. The audit fee is estimated at RMB 7.00 million–8.00 million, exclusive of out-of-pocket expenses.

4. Administrative Details • Share register closure: 24–29 June 2026 (both days inclusive). • Proxy forms must reach Computershare Hong Kong Investor Services by 10:00 a.m. on 27 June 2026. • All AGM voting will be conducted by poll.

5. Recent Buy-backs Between 15–26 May 2026 the company repurchased 11.61 million shares on-market at prices ranging from HK$ 38.44 to HK$ 45.30.

6. Major Shareholder Position As of the latest practicable date, Chairman Richard Qiangdong Liu held or controlled approximately 70.04% of issued shares. Full utilisation of the repurchase mandate would raise his aggregate holding to about 77.79%, still below the level that would trigger a mandatory offer under Hong Kong’s Takeovers Code.

No shareholder is required to abstain from voting on the proposed resolutions. The board recommends approval of all items.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10